---
title: "Alpha Tau Medical Ltd. (TASE:DRTS) Posts Strong Early Cancer Trial Signals; Key Readouts Ahead"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299216743.md"
description: "Alpha Tau Medical reported early positive signals in head & neck, brain, and pancreatic cancer trials. Head & neck combination therapy showed a 100% response rate, while glioblastoma results included two complete responses. The company has $104.8M in cash to support ongoing studies. Three major data readouts are expected between late 2026 and early 2027, including pivotal skin cancer data."
datetime: "2026-09-16T17:37:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299216743.md)
  - [en](https://longbridge.com/en/news/299216743.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299216743.md)
generator: "portal-rs"
---

# Alpha Tau Medical Ltd. (TASE:DRTS) Posts Strong Early Cancer Trial Signals; Key Readouts Ahead

Alpha Tau Medical reports early positive signals across head & neck, brain, and pancreatic cancer studies, with three major data readouts expected around late 2026 to early 2027.

**Material Details**

| # | Detail                               | AI Analyst View                                                                                           |
| - | ------------------------------------ | --------------------------------------------------------------------------------------------------------- |
| 1 | H&N combo shows 100% response (n=9)  | Unusually high response vs typical 19% for pembrolizumab alone; could reshape expectations if replicated. |
| 2 | Median OS 18.2m vs 12.3m historical  | Suggests additive benefit; survival is the key clinical and commercial endpoint.                          |
| 3 | Glioblastoma: 2 CRs, 1 PR (n=3)      | Early but striking in a hard-to-treat cancer; FDA cleared trial to complete enrollment.                   |
| 4 | Pancreatic IMPACT expanded to 48 pts | Physician demand and rapid enrollment increase the program’s visibility and potential.                    |
| 5 | Three readouts due by early 2027     | Clustered catalysts: skin (pivotal), pancreas (48-pt data), brain (additional data).                      |
| 6 | Cash $104.8M as of Jun 30            | Runway supports near-term trials; reduces financing overhang into data.                                   |

**Context by AI Analyst**

This is early-to-mid stage validation across multiple indications, with a pivotal skin cancer trial as the nearest regulatory path. For a larger catalyst, pivotal ReSTART data and full 48-patient pancreatic readout must confirm efficacy and safety at scale.

Based on the original press release from Alpha Tau Medical Ltd. distributed by FinanceWire.

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Summary is based on content distributed by FinanceWire. Please verify any important information with the original source. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [DRTS.US](https://longbridge.com/en/quote/DRTS.US.md)
- [DRTSW.US](https://longbridge.com/en/quote/DRTSW.US.md)

## Related News & Research

- [Alpha Tau completes enrollment in 48-patient IMPACT pancreatic cancer Alpha DaRT pilot study](https://longbridge.com/en/news/297513505.md)
- [Alpha Tau Posts Strong Alpha DaRT–Keytruda Data in Head and Neck Cancer Study](https://longbridge.com/en/news/293346278.md)
- [Micron Stock's (MU) AI Lead Is Expanding beyond HBM. I'm Bullish](https://longbridge.com/en/news/299626350.md)
- [Michael Saylor Says, 'A Little More Orange': Will Strategy Report BTC Purchases After Hitting Pause for 3 Weeks?](https://longbridge.com/en/news/299601303.md)
- [Jensen Huang Says AI CEOs May Have 'Ulterior', Maybe 'Political' Reasons For AI Doomsday Warnings: 'Go and Read Between The Lines'](https://longbridge.com/en/news/299637656.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**